Literature DB >> 11226949

Computed tomography imaging of the maxillary and ethmoid sinuses in children with short-duration purulent rhinorrhea.

R H Schwartz1, A Pitkaranta, B Winther.   

Abstract

INTRODUCTION: Adults with a common cold often have paranasal sinus effusions detected by computed tomographic (CT) scans. There are no comparable data for children. The purpose of this study was to document the sinus CT findings in children with short-duration purulent rhinorrhea.
DESIGN: Thirty children, 3 to 12 years of age (median age, 7 years), with purulent rhinorrhea for a mean duration of 5 days (and always less than 9 days) were enrolled in the study. The children were otherwise well. Institutional Review Board (IRB)-approval was obtained before enrollment of the first patient. Informed written consent was obtained from each child's parent. CT imaging of the maxillary and ethmoid sinuses was obtained on the day of the initial visit (occasionally, the following day). Follow-up CT scans were obtained from cooperative children/parents, 3 to 4 weeks later.
RESULTS: Opacification or an air/fluid level in the maxillary sinuses was seen in 27 (90%) of 30 study children at study entry. Ethmoid sinuses were not opacified without opacification of a maxillary sinus. Three weeks later, 24 of 27 study children, who had positive CT scans on study entry, improved clinically. Of 17 follow-up CT scans, 10 (58%) normalized, 4 had improvement of bilateral disease, and 3 improved with unilateral disease. None appeared worse than baseline.
CONCLUSIONS: Pansinus opacification (ethmoid and maxillary sinuses), on CT scans in children with short-duration purulent nasal drainage was seen in 70% of children. An additional 20% had isolated maxillary sinus effusions (10% had no effusion). Three-week follow-up CT scans on 17 children were normal in 60% and improved (partial clearance) in 40%. In this patient population, the decision to treat with antibiotics should be made on clinical grounds alone.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11226949     DOI: 10.1067/mhn.2001.112879

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  7 in total

1.  Bacteria in the nose of young adults during wellness and rhinovirus colds: detection by culture and microarray methods in 100 nasal lavage specimens.

Authors:  E Kaitlynn Allen; Anne Pitkäranta; Minna Mäki; J Owen Hendley; Sanna Laakso; Michèle M Sale; Birgit Winther
Journal:  Int Forum Allergy Rhinol       Date:  2013-06-25       Impact factor: 3.858

Review 2.  Current research on respiratory viral infections: Fourth International Symposium.

Authors:  Michael G Ison; John Mills; Peter Openshaw; Maria Zambon; Albert Osterhaus; Frederick Hayden
Journal:  Antiviral Res       Date:  2002-08       Impact factor: 5.970

3.  Characterization of the nasopharyngeal microbiota in health and during rhinovirus challenge.

Authors:  E Kaitlynn Allen; Alex F Koeppel; J Owen Hendley; Stephen D Turner; Birgit Winther; Michèle M Sale
Journal:  Microbiome       Date:  2014-06-25       Impact factor: 14.650

4.  Chronic rhinosinusitis: correlation of symptoms with computed tomography scan findings.

Authors:  Enema Job Amodu; Ayotunde James Fasunla; Aliu Oyebamiji Akano; Abiodun Daud Olusesi
Journal:  Pan Afr Med J       Date:  2014-05-10

Review 5.  [Current management of acute pediatric rhinosinusitis in France].

Authors:  J-M Klossek; B Quinet; E Bingen; M François; J Gaudelus; S Larnaudie; F Liard; Y Péan; G Roger; O Reveillaud; E Serrano
Journal:  Med Mal Infect       Date:  2007-02-21       Impact factor: 2.152

Review 6.  Viral upper respiratory tract infections in young children with emphasis on acute otitis media.

Authors:  Johanna Nokso-Koivisto; Tapani Hovi; Anne Pitkäranta
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2006-03-27       Impact factor: 1.675

Review 7.  Treatment of pediatric sinusitis.

Authors:  Ari J Goldsmith; Richard M Rosenfeld
Journal:  Pediatr Clin North Am       Date:  2003-04       Impact factor: 3.278

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.